Loading...
XNAS
SVRA
Market cap989mUSD
Oct 08, Last price  
4.83USD
1D
-1.02%
1Q
-19.90%
Jan 2017
-20.51%
IPO
-99.86%
Name

Savara Inc

Chart & performance

D1W1MN
XNAS:SVRA chart
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
30.26%
Rev. gr., 5y
25.99%
Revenues
0
0500,000500,000300,000488,9590001,54854400,000000257,00000000
Net income
-119m
L+23.94%
-29,331,773-22,142,040-26,647,493-11,325,058-8,450,922-13,260,000-15,559,489-21,480,285-28,702,000-39,842,000-10,923,000-29,797,000-61,516,000-78,173,000-49,615,000-43,014,000-38,150,000-54,698,000-95,881,000-118,837,000
CFO
-101m
L+13.41%
-15,773,544-19,643,190-23,787,604-12,616,416-8,341,237-13,466,954-13,918,868-17,788,962-24,645,000-32,949,000-8,370,000-28,234,000-39,275,000-45,123,000-39,836,000-40,081,000-34,554,000-51,061,000-89,088,000-101,037,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.

Key people

Matthew Pauls
Chairman of the Board, Chief Executive Officer · since 2020
Robert Lutz
Chief Operating Officer · since 2023
David Lowrance
Chief Financial and Administrative Officer, Secretary · since 2022
Anne Erickson
Chief Business Officer · since 2024
Kate Mccabe
Chief Legal Officer · since 2024
Braden Parker
Chief Commercial Officer · since 2024
Raymond Pratt
Chief Medical Officer · since 2022
Nevan Elam
Independent Director · since 2009
Richard Hawkins
Independent Director · since 2010
Joseph Mccracken
Lead Independent Director · since 2019
David Ramsay
Independent Director · since 2017
Annigje van Es-Johansson
Independent Director · since 2019
URL
https://savarapharma.com/
IPO date
Jun 25, 2001
Employees
28
Domiciled in
US
Incorporated in
US
Legal address
c/o CORPORATION SERVICE COMPANY, 251 LITTLE FALLS DRIVE
WILMINGTON, DE 19808
US
Headquarters
6836 FM 2244 RD BLDG 3-201
Austin, TX 78746-5577
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT